Shareholding disclosure

Cosmo Pharmaceuticals NV

Declared position

96.48%

Threshold

Crossed upwards

Timeline

Published

10.12.2021

Transaction

02.12.2021

Transfer date

17.12.2021

Voting rights breakdown

Voting rights acquired96.48%

Voting rights sold0%

Below threshold0%

Notice details

CategorySingle shareholder

ExchangeXSWX

Notification ID

TALC900064

Beneficial owner

Cosmo Pharmaceuticals NV

Declared address

Cosmo Pharmaceuticals N.V., Dublin 2

Open shareholder profile Open company profile

Back to the feed

Shareholding disclosure

Cosmo Pharmaceuticals NV

Cassiopea S.p.A.10.12.2021TALC900064

Disclosure summary

Cosmo Pharmaceuticals NV disclosed a holding in Cassiopea S.p.A. on the acquisition side, published by SIX Exchange Regulation on 10.12.2021, at 96.48% of voting rights. Notice category: Single shareholder.

Disclosed position

96.48%

Voting rights acquired

Voting rights acquired96.48%

Voting rights sold0%

Below threshold0%

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open

Disclosure detail

Cosmo Pharmaceuticals NV disclosed a holding in Cassiopea S.p.A., published on 10.12.2021.

Publication date10.12.2021

Transaction date02.12.2021

Transfer date17.12.2021

Issuing companyCassiopea S.p.A.

Beneficial ownerCosmo Pharmaceuticals NV

Declared addressCosmo Pharmaceuticals N.V., Dublin 2

CategorySingle shareholder

Voting rights acquired96.48%

Voting rights sold0%

Below threshold0%

ExchangeXSWX

Notification IDTALC900064

Source: SIX Exchange Regulation · Publication date: 10.12.2021

These figures aggregate public disclosures. They are not investment advice.

insider24.ch

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open